Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20μg and Drospirenone 3mg

被引：0

作者：

D. Cibula

U. Karck

H. G. Weidenhammer

J. Kunz

S. Alincic

J. Marr

机构：

[1] Charles University,Department of Obstetrics and Gynaecology, General Faculty Hospital

[2] University of Freiburg,Department of Obstetrics and Gynaecology

[3] Klarastr,undefined

[4] Hospital Zollikerberg,undefined

[5] Schering AG,undefined

[6] MDG G&A,undefined

来源：

Clinical Drug Investigation | 2006年 / 26卷

关键词：

Combine Oral Contraceptive; Contraceptive Efficacy; Drospirenone; Withdrawal Bleeding; Normal Menstruation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: The purpose of this study was to assess the efficacy and safety of a new low-dose oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg (EE 20μg/drsp 3mg).

引用

页码：143 / 150

页数：7

共 38 条

[21] The influence of a combined low dose oral contraceptive containing drospirenone on electrolite equlibrum and renal function in young woman
Szlendak-Sauer, Katarzyna
Radowicki, Stanislaw
Skorzewska, Katarzyna
GINEKOLOGIA POLSKA, 2009, 80 (01) : 33 - 37
[22] Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen
Marr, Joachim
Niknian, Minoo
Shulman, Lee P.
Lynen, Richard
CONTRACEPTION, 2011, 84 (01) : 81 - 86
[23] Efficacy and Safety of the Combined Oral Contraceptive Ethinylestradiol/Drospirenone (Yasmin®) in Healthy Chinese Women A Randomized, Open-Label, Controlled, Multicentre Trial
Fan Guang-Sheng
Bian Mei-Lu
Cheng Li-Nan
Cao Xiao-Ming
Huang Zi-Rong
Han Zi-Yan
Jing Xiao-Ping
Li Jian
Wu Shu-Ying
Xiong Cheng-Liang
Xiong Zheng-Ai
Yue Tian-Fu
CLINICAL DRUG INVESTIGATION, 2010, 30 (06) : 387 - 396
[24] Effect of an oral contraceptive containing 30 μg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention
Fruzzetti, Franca
Lazzarini, Veronica
Ricci, Cabiria
Quirici, Barbara
Gambacciani, Marco
Paoletti, Anna Maria
Genazzani, Andrea Riccardo
CONTRACEPTION, 2007, 76 (03) : 190 - 194
[25] Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial
Koltun, William
Lucky, Anne W.
Thiboutot, Diane
Niknian, Minoo
Sampson-Landers, Carole
Korner, Paul
Marr, Joachim
CONTRACEPTION, 2008, 77 (04) : 249 - 256
[26] Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive
Anttila, Leena
Kunz, Michael
Marr, Joachim
CONTRACEPTION, 2009, 80 (05) : 445 - 451
[27] An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen
Parsey, KS
Pong, A
CONTRACEPTION, 2000, 61 (02) : 105 - 111
[28] Hormone withdrawal-associated symptoms with ethinylestradiol 20 mu g/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 mu g/desogestrel 150 mu g (21/7 regimen)
Bitzer, Johannes
Banal-Silao, Maria Jesusa
Ahrendt, Hans-Joachim
Restrepo, Jaime
Hardtke, Marion
Wissinger-Graefenhahn, Ulrike
Trummer, Dietmar
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 501 - 509
[29] The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese users
Creinin, Mitchell D.
Angulo, Alicyoy
Colli, Enrico
Archer, David F.
CONTRACEPTION, 2023, 128
[30] An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 μg ethinylestradiol and 150 μg levonogestrel/30 μg ethinylestradiol in Thai women
Suthipongse, W
Taneepanichskul, S
CONTRACEPTION, 2004, 69 (01) : 23 - 26

← 1 2 3 4 →